(vascular endothelial growth factor A/VEGF-A inhibitor) has shown increased efficacy with a reported ORR of 27% in the recent IMBrave150 trial [13], the best systemic therapies for HCC confer ORRs and OS that compare poorly with treatments for other solid organ cancers. This evidence concerns the gene VEGFA and hepatocellular carcinoma.